Better design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
Authors:
Open Access
- 9 January 2023
- journal article
- editorial
- Published by Wiley in Pediatric Investigation
- Vol. 7 (1) , 1-5
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19New England Journal of Medicine, 2021
- Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trialsJournal of Microbiology, Immunology and Infection, 2021
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trialInternational Journal of Infectious Diseases, 2021
- Progresses in clinical studies on antiviral therapies for COVID‐19—Experience and lessons in design of clinical trialsPediatric Investigation, 2020
- A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19Antimicrobial Agents and Chemotherapy, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Antiviral Drugs Underused in US Patients for 2009 Influenza A(H1N1) Pandemic2011
- Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the United StatesPLoS Currents, 2009